PMID- 29159466
OWN - NLM
STAT- MEDLINE
DCOM- 20180907
LR  - 20211204
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Linking)
VI  - 265
IP  - 4
DP  - 2018 Apr
TI  - Efficacy and safety of perampanel in Parkinson's disease. A systematic review 
      with meta-analysis.
PG  - 733-740
LID - 10.1007/s00415-017-8681-y [doi]
AB  - BACKGROUND: L-Dopa represents the mainstay of therapy of Parkinson's disease 
      (PD), but its effectiveness is reduced with continued treatment and disease 
      progression. Accordingly, there remains a need to explore novel treatment 
      strategies to manage the signs and symptoms of the later disease stages. The aim 
      of the study was to evaluate the efficacy and safety of adjunctive perampanel 
      (PER) in patients with PD through a meta-analysis of existing trials. METHODS: 
      Randomized, placebo-controlled, double- or single-blind, add-on studies of PER in 
      patients with PD were identified through a systematic literature search. The 
      following outcomes were assessed: changes from baseline to final efficacy visit 
      in total daily OFF time, activities of daily living during OFF time and motor 
      function during ON time, incidence of adverse events (AEs), and treatment 
      withdrawal. RESULTS: Four trials were included involving 2266 participants, 1449 
      and 817 for PER and placebo treatment groups, respectively. Four PER daily doses 
      were tested, namely 0.5, 1, 2 and 4 mg. There were no significant differences in 
      any efficacy outcome between PER and placebo treated patients. The risk ratios 
      (RRs) for AEs, severe AEs and treatment withdrawal were similar between placebo 
      and PER at 0.5, 1 and 2 mg; the 4 mg daily dose was associated with an increased 
      risk of AEs [RR 1.118 (1.047-1.193)], and withdrawal for AEs [RR 1.345 
      (1.034-1.749)] and for any reason [RR 1.197 (1.020-1.406)]. CONCLUSIONS: In PD 
      patients experiencing motor fluctuations, adjunctive PER did not improve the 
      motor state and was well-tolerated at the lower doses.
FAU - Lattanzi, Simona
AU  - Lattanzi S
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Via Conca 71, 60020, Ancona, Italy. 
      alfierelattanzisimona@gmail.com.
FAU - Grillo, Elisabetta
AU  - Grillo E
AD  - Medical Department Eisai s.r.l, San Donato Milanese, Italy.
FAU - Brigo, Francesco
AU  - Brigo F
AD  - Department of Neuroscience, Biomedicine and Movement Science, University of 
      Verona, Verona, Italy.
AD  - Division of Neurology, "Franz Tappeiner" Hospital, Merano, BZ, Italy.
FAU - Silvestrini, Mauro
AU  - Silvestrini M
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Via Conca 71, 60020, Ancona, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20171120
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Nitriles)
RN  - 0 (Pyridones)
RN  - H821664NPK (perampanel)
SB  - IM
MH  - Activities of Daily Living
MH  - Antiparkinson Agents/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Humans
MH  - Nitriles
MH  - Parkinson Disease/*drug therapy/psychology
MH  - Pyridones/*therapeutic use
MH  - Single-Blind Method
OTO - NOTNLM
OT  - Dyskinesia
OT  - Movement disorders
OT  - Parkinson's disease
OT  - Perampanel
EDAT- 2017/11/22 06:00
MHDA- 2018/09/08 06:00
CRDT- 2017/11/22 06:00
PHST- 2017/09/13 00:00 [received]
PHST- 2017/11/14 00:00 [accepted]
PHST- 2017/11/09 00:00 [revised]
PHST- 2017/11/22 06:00 [pubmed]
PHST- 2018/09/08 06:00 [medline]
PHST- 2017/11/22 06:00 [entrez]
AID - 10.1007/s00415-017-8681-y [pii]
AID - 10.1007/s00415-017-8681-y [doi]
PST - ppublish
SO  - J Neurol. 2018 Apr;265(4):733-740. doi: 10.1007/s00415-017-8681-y. Epub 2017 Nov 
      20.